StreetAlpha.app
Home › Stocks › APRE

Aprea Therapeutics, Inc. (APRE)

Members
LATEST PRICE

Aprea Therapeutics develops cancer drugs that target specific genetic mutations in tumors. APRE reports earnings on Wed, Nov 11, 2026.

Prices, price targets and earnings estimates for APRE are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is APRE in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 11
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated APRE in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for APREThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
Ladenburg ThalmannInitiated
Oct 14Buy
WedbushMaintained
Aug 13Buy
OppenheimerInitiated
May 7Buy
DateFirmActionRatingPrice target
Oct 14Ladenburg ThalmannInitiatedBuy
Aug 13WedbushMaintainedBuy
May 7OppenheimerInitiatedBuy
Loading…

Seasonality

How APRE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in APRE in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether APRE is in one of them and how their past APRE trades turned out.

See how it works→ View all auto pilots→
APRE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered APRE in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Aprea Therapeutics

Aprea Therapeutics is a pharmaceutical company based in Doylestown, Pennsylvania, that develops cancer drugs. It focuses on treatments designed to target specific genetic mutations found in certain tumors. Its lead candidates are small molecule drugs, APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, which are in clinical trials. The company aims these treatments at patients whose cancers carry particular mutations, and its drugs are still in development.

Headquarters
Doylestown, PA
Summary based on the company’s 2026 annual report (10-K) ↗